
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF84 (zinc finger protein 84) encodes a zinc finger protein with predicted DNA-binding and zinc ion-binding activities. It is predicted to participate in regulation of DNA-templated transcription and to localize to the nucleus. These characteristics are consistent with a potential role in transcriptional regulation, although the specific molecular targets and biological processes controlled by ZNF84 remain incompletely characterized.
T98G is a human glioblastoma multiforme cell line derived from a tumor of a 61-year-old male patient. The cells exhibit an indefinite lifespan and anchorage-independent growth properties, while retaining the ability to enter a viable G1-arrested state under serum deprivation conditions. T98G is used as a model for studying glioblastoma biology, cell cycle regulation, tumor growth mechanisms, and therapeutic responses.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?